nemo wrote: ↑Sat Jun 26, 2021 9:48 am

This is June now. Things have changed drastically.

How so?
Please cite a source.

Latest news blaming the Delta variant
Hundreds of vaccinated Indonesian health workers get Covid-19, dozens in hospital

Story by Reuters

Updated 1236 GMT (2036 HKT) June 18, 2021
A healthcare worker prepares a dose of the Sinovac Covid-19 vaccine at Bogor Regional Public Hospital in Bogor, Indonesia, on January 14.

More than 350 doctors and medical workers have caught Covid-19 in Indonesia despite being vaccinated with Sinovac, officials said, as concerns grow about the efficacy of some vaccines against more infectious variants.
Most of the workers were asymptomatic and self-isolating at home, said Badai Ismoyo, head of the health office in the district of Kudus in central Java, but dozens have been hospitalized with high fevers and falling oxygen-saturation levels.
Kudus, which has about 5,000 healthcare workers, is battling an outbreak believed to be driven by the more transmissible Delta variant, which has raised its bed occupancy rates above 90%.
https://edition.cnn.com/2021/06/18/asia ... index.html

Good explanatory article -

What are the Sinopharm and Sinovac vaccines? And how effective are they? Two experts explain
June 21, 2021 7.20pm AEST

What was their efficacy in clinical trials?

Sinovac’s efficacy at preventing symptomatic infection was 51% in Brazil, 67% in Chile, 65% in Indonesia, and 84% in Turkey. The differences in results may be due to different variants circulating in each country at the time and differences in the populations included in the studies.

Sinopharm’s efficacy in preventing symptomatic infection was 78% in UAE, Bahrain, Egypt and Jordan combined.

As with all the COVID-19 vaccines for which data are available, efficacy against the more severe outcomes is greater. Efficacy against hospitalisation for Sinovac in Chile, Brazil and Turkey was 85%, 100% and 100%, respectively.

However, few elderly people with underlying health issues were enrolled into these studies.

For Sinopharm, efficacy against hospitalisation was 79%, although few women were enrolled in these studies.
https://theconversation.com/what-are-th ... ain-162258

How effective are they in the real world? Note emerging mutations will most likely affect these figures

Data published in April from a large real world study in Chile suggests Sinovac is 67% effective in preventing symptomatic COVID-19 infection. It’s effectiveness against hospitalisation was 85%, ICU admission 89%, and death 80%.

Sinopharm’s effectiveness against symptomatic infection in Bahrain was 90%.
https://theconversation.com/what-are-th ... ain-162258

Kuroneko wrote: ↑Sat Jun 26, 2021 10:00 am

nemo wrote: ↑Sat Jun 26, 2021 9:48 am

This is June now. Things have changed drastically.

How so?
Please cite a source.

Latest news blaming the Delta variant
Hundreds of vaccinated Indonesian health workers get Covid-19, dozens in hospital

Story by Reuters

Updated 1236 GMT (2036 HKT) June 18, 2021
A healthcare worker prepares a dose of the Sinovac Covid-19 vaccine at Bogor Regional Public Hospital in Bogor, Indonesia, on January 14.

More than 350 doctors and medical workers have caught Covid-19 in Indonesia despite being vaccinated with Sinovac, officials said, as concerns grow about the efficacy of some vaccines against more infectious variants.
Most of the workers were asymptomatic and self-isolating at home, said Badai Ismoyo, head of the health office in the district of Kudus in central Java, but dozens have been hospitalized with high fevers and falling oxygen-saturation levels.
Kudus, which has about 5,000 healthcare workers, is battling an outbreak believed to be driven by the more transmissible Delta variant, which has raised its bed occupancy rates above 90%.
https://edition.cnn.com/2021/06/18/asia ... index.html

(From the May article)

Indonesia tracked 128,290 health workers in capital city Jakarta from January to March and found that the vaccine protected 98% of them from death and 96% from hospitalization as soon as seven days after the second dose, Pandji Dhewantara, a Health Ministry official who oversaw the study, said in a Wednesday press conference.

What is the score with the 128,290?

A selective sample of 5000 in one area with unknown protocols and post vaccination behaviour* should be viewed with caution. Until they report on a much larger number of cohorts this gets a large pinch of salt.

*Many are now experiencing pandemic fatigue and taking a less vigilant approach to health protocols after being vaccinated, said Lenny Ekawati from LaporCovid-19